Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Carvedilol does not reduce cocaine use in methadone-maintained cocaine users.

Sofuoglu M, Poling J, Babuscio T, Gonsai K, Severino K, Nich C, Carroll KM.

J Subst Abuse Treat. 2017 Feb;73:63-69. doi: 10.1016/j.jsat.2016.11.005. Epub 2016 Nov 17.

PMID:
28017186
2.

Impact of gender on corticotropin-releasing factor and noradrenergic sensitivity in cocaine use disorder.

McRae-Clark AL, Cason AM, Kohtz AS, Moran Santa-Maria M, Aston-Jones G, Brady KT.

J Neurosci Res. 2017 Jan 2;95(1-2):320-327. doi: 10.1002/jnr.23860. Review.

PMID:
27870396
3.

Effects of MDMA on body temperature in humans.

Liechti ME.

Temperature (Austin). 2014 Oct 31;1(3):192-200. doi: 10.4161/23328940.2014.955433. eCollection 2014 Oct-Dec.

4.

Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers.

Verrico CD, Mahoney JJ 3rd, Thompson-Lake DG, Bennett RS, Newton TF, De La Garza R 2nd.

Int J Neuropsychopharmacol. 2014 Feb;17(2):223-33. doi: 10.1017/S146114571300134X.

5.

The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study.

Shorter D, Lindsay JA, Kosten TR.

Drug Alcohol Depend. 2013 Jul 1;131(1-2):66-70. doi: 10.1016/j.drugalcdep.2012.11.021. Epub 2013 Jan 8.

6.

Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Hysek C, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, Liechti ME.

Br J Pharmacol. 2012 Aug;166(8):2277-88. doi: 10.1111/j.1476-5381.2012.01936.x.

7.

Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Haile CN, Mahoney JJ 3rd, Newton TF, De La Garza R 2nd.

Pharmacol Ther. 2012 May;134(2):260-77. doi: 10.1016/j.pharmthera.2012.01.010. Epub 2012 Jan 31. Review.

8.

Rethinking cocaine-associated chest pain and acute coronary syndromes.

Finkel JB, Marhefka GD.

Mayo Clin Proc. 2011 Dec;86(12):1198-207. doi: 10.4065/mcp.2011.0338. Review.

9.

New medications for the treatment of cocaine dependence.

Kampman KM.

Psychiatry (Edgmont). 2005 Dec;2(12):44-8.

10.

Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for β-2 adrenergic receptors.

Mantsch JR, Weyer A, Vranjkovic O, Beyer CE, Baker DA, Caretta H.

Neuropsychopharmacology. 2010 Oct;35(11):2165-78. doi: 10.1038/npp.2010.86. Epub 2010 Jul 7.

11.

Norepinephrine and stimulant addiction.

Sofuoglu M, Sewell RA.

Addict Biol. 2009 Apr;14(2):119-29. doi: 10.1111/j.1369-1600.2008.00138.x. Epub 2008 Sep 22. Review.

12.

The search for medications to treat stimulant dependence.

Kampman KM.

Addict Sci Clin Pract. 2008 Jun;4(2):28-35.

13.

The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers.

De La Garza R 2nd, Mahoney JJ 3rd, Culbertson C, Shoptaw S, Newton TF.

Pharmacol Biochem Behav. 2008 Apr;89(2):200-8. doi: 10.1016/j.pbb.2007.12.010. Epub 2008 Jan 22.

14.

Effects of perceived cocaine availability on subjective and objective responses to the drug.

Yamamoto RT, Karlsgodt KH, Rott D, Lukas SE, Elman I.

Subst Abuse Treat Prev Policy. 2007 Oct 11;2:30.

15.

A qualitative and quantitative review of cocaine-induced craving: the phenomenon of priming.

Mahoney JJ 3rd, Kalechstein AD, De La Garza R 2nd, Newton TF.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):593-9. Epub 2007 Jan 31. Review.

Supplemental Content

Support Center